The pharma major beat analysts’ expectations in the fourth quarter of 2024, despite looming competition for its top heart ...

The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization ...

By Nikhil Sharma (Reuters) -European shares reached a record high on Friday, led by technology and healthcare stocks, as ...

Novartis AG (NVS) reports robust financial performance with significant product sales growth, while addressing potential ...

Novartis Ag (NYSE: NVS) Q4 2024 Earnings Call Jan 31, 2025, 8:00 a.m. ET ...

Novartis chief executive says large pharma deals usually don't pay off. But the company remains interested in bolt-on ...

One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

Ionis Pharmaceuticals (IONS) stock slips as Novartis (NVS) delays Phase 3 trial data for its cardiac therapy pelacarsen. Read ...

CEO Vas Narasimhan highlighted Novartis' strong performance in Q4 2024, with sales increasing 16% and core operating income rising 29% in constant currency. For the full year, the company achieved a ...

Select listed pharma player including Pfizer, Novartis India, AstraZeneca Pharma and GSK Pharma shall be the beneficiaries of ...

The list of 36 drugs, which are exempt from basic customs duty, includes many expensive and imported medicines that can ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.